Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle
Suite 1250
Coral Gables, Florida 33134
January 6, 2017
VIA EDGAR AND E-MAIL
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
| Re: | Catalyst Pharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed on December 23, 2016
Registration No. 333-215315
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Catalyst Pharmaceuticals, Inc. hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated to 10:00 a.m., Washington, D.C. time, on Monday, January 9, 2017, or as soon thereafter as is practicable.
Please call Philip Schwartz (at 954-468-2455) at Akerman LLP as soon as the Registration Statement has been declared effective.
Thank you for your courtesy and cooperation.
| Very Truly Yours, |
| /s/ Patrick J. McEnany |
| Patrick J. McEnany |
| Chairman, President and CEO |
| Cc: | Mary Beth Breslin (SEC) |
Dorrie Yale (SEC)